8 results about "Opioid" patented technology

The invention provides a method for preparing an opioid reduzate intermediate and application of the opioid reduzate intermediate. The method comprises the following steps: carrying out first reduction reaction on hydrazine hydrate and hydrogen peroxide; the product in the step (1) and a compound shown in a formula I are subjected to a second reduction reaction, a compound shown in a formula II is obtained, and the first reduction reaction and the second reduction reaction are carried out in a continuous flow reactor; r1 is selected from carbonyl and-C-OR5, R5 is selected from hydrogen, C1-20 alkyl, hetero-alkyl and carbonyl, R2 is selected from hydrogen, C1-20 alkyl, hetero-alkyl and carbonyl, R3 is selected from hydrogen, C1-20 alkyl, aryl, hetero-aryl, cycloalkyl, hetero-alkyl, aryl alkyl or hetero-aryl alkyl, and R4 is selected from hydrogen and hydroxyl. According to the method, hydrogen peroxide and hydrazine hydrate in a specific proportion are mixed in a continuous flow reactor, diazene is obtained in situ, diazene reduction replaces hydrogenation reduction reaction, operation is safe and stable, the product yield is high, impurities are few, cost is low, and the method is suitable for industrial large-scale production.

The application discloses a kind of imide compounds for the photoactivation fluorescent detection method of opioid, comprising the following steps: S1, 1-100 equivalent imide compound, 10-10000 equivalent opioid and 0-100000 equivalent solvent are mixed, and mixture is prepared;S2, using 200nm-500nm light source or natural light is irradiated 5s-5000s to the mixture in S1 at room temperature, fluorescence phenomenon can be detected.This application will amide derivative (solid or liquid), opioid (solid or liquid) and solvent are mixed, under the irradiation of specific wavelength and power light source, imide molecule and the specific structure between drug molecule form similar to exciplex photo-irradiation product, the product will produce structure-dependent fluorescence, to carry out the specific recognition of drug molecule.The method is simple in operation, and sensitivity is high, specificity is strong, so opioid can be efficiently and rapidly qualitatively detected.

The present application belongs to the technical field of drug detection method, and particularly relates to a method for detecting drugs in atmospheric environment samples, comprising the following steps: using the adsorption material of a gas sampling instrument to adsorb the drugs in the gas; after the material adsorbs the drugs, using ultrasonic extraction in an organic solvent or a high-temperature heating method to resolve the drugs; and using high-sensitivity mass spectrometry, molecular immunocolloidal gold or fluorescence method to detect the resolved drugs. The detection method can qualitatively and quantitatively detect the drugs in the atmosphere, and is also suitable for detecting the drugs in the exhaled gas of drug users, and contains new psychoactive drugs such as amphetamines, opioids and synthetic cannabis.

To provide a pharmaceutical product useful for the treatment or prevention of opioid δ receptor-related diseases. [Solution] The present invention relates to a pharmaceutical composition comprising a morphinan derivative that exerts opioid δ receptor agonist activity. By administering the pharmaceutical composition provided by the present invention, opioid δ receptor-related diseases (e.g., headaches) may be treated or prevented.

(Main claim) Disposal container for the irreversible deactivation of anesthetic drug residues, comprising a multi-layered binding system arranged from top to bottom and including: 1. an upper layer of adsorbent and / or ion exchange resin, 2. a middle layer of activated carbon or another adsorption matrix, 3. a lower layer of a polymer gel for solidifying residual liquids, the layers are designed in such a way that propofol, opioids and ketamine are bound and solidified sequentially, and recovery of the active ingredients is impossible.

Cannabinoids and terpenoids, which are non-psychoactive elements found in stressed plants, are being studied as possible supplemental treatments for symptoms of drug withdrawal related to remodeling. The therapeutic properties, in addition to reducing cue-induced drug cravings, are very relevant to opioid, cocaine, or cannabis withdrawal syndromes and should be included in standard detoxification programs to mitigate the symptoms of drug withdrawal. Since there is no way to stop this addiction without suffering from serious adverse effects or developing a self-addiction to pharmacological therapies, opioids, cocaine, and cannabis are extremely addictive substances. Using low-dose mixtures of terpenes, terpenoids, and cannabinoids, this innovation seeks to provide a revolutionary anti-addictive analgesic regimen that will safely and effectively cure individuals who are addicted to opioids, cannabinoids, cocaine, or self-addictive substances. Blocking the effects of addiction by inhibiting physiological metabolic processes, these compounds have safe and effective pharmacological, neurobiological, and psychological mechanisms for curing addiction.

The application provides a novel peptide multi-target ligand molecule based on a kappa-opioid and sigma 1 receptor system, the ligand is a multi-target ligand based on a kappa-opioid / sigma 1 receptor system obtained by using a kappa-opioid receptor agonist CR845 and a sigma 1 receptor antagonist S1RA as chemical template molecules and sharing a pharmacophore. Animal in-vivo pharmacological identification shows that the multi-target peptide ligand of the application can produce analgesic effect in various preclinical pain models, the kappa-like side effects of sedation and depression are reduced compared with the template molecule CR845, and there is no side effect of analgesic tolerance. Therefore, the multi-target ligand based on the kappa-opioid and / or sigma 1 receptor system provided by the application has the value of developing a new analgesic drug with low side effects.